Content about Francisco

March 24, 2014

Genentech announced that the Food and Drug Administration approved Xolair (omalizumab) for the treatment of chronic idiopathic urticaria, or CIU, which is a form of chronic hives.

SOUTH SAN FRANCISCO, Calif. — Genentech announced that the Food and Drug Administration approved Xolair (omalizumab) for the treatment of chronic idiopathic urticaria, or CIU, which is a form of chronic hives.

CIU is diagnosed when hives occur without cause, spontaneously present and reoccur for more than six weeks, the company said. The symptoms include swelling, severe itch, pain and discomfort that may last for months and, in some cases, years. 

March 13, 2014

Beauty retailer Sephora has unveiled its new Beauty Board, a social shopping platform to engage shoppers through beauty images and allow them to post, share, browse and shop Sephora’s photo gallery directly on the retailer's web site, the mobile site, iPhone and Android apps.

SAN FRANCISCO, Calif. — Beauty retailer Sephora has unveiled its new Beauty Board, a social shopping platform to engage shoppers through beauty images and allow them to post, share, browse and shop Sephora’s photo gallery directly on the retailer's web site, the mobile site, iPhone and Android apps.

December 18, 2013

Actelion has launched a topical gel used to treat a kind of skin cancer, the company said.

SOUTH SAN FRANCISCO, Calif. – Actelion has launched a topical gel used to treat a kind of skin cancer, the company said.

Actelion announced the launch of Valchlor (mechlorethamine), which the Food and Drug Administration approved in August for treating stage 1A and 1B mycosis fungoides-type cutaneous T-cell lymphoma in patient who have received skin-directed therapy before. Actelion acquired rights to the drug when it merged with Ceptaris Therapeutics. Accredo Specialty Pharmacy distributes the drug in the United States.

November 8, 2013

Higi ‘scores’ with kiosks

Through its biometric screening kiosks, its smartphone application and its website, Higi encourages users to take a more holistic approach to their health. True wellness, its creators insist, springs not just from such physical metrics as blood pressure, glucose readings and body mass index, but from lifestyle choices and connections to family, friends, neighbors and coworkers.

October 24, 2013

The Food and Drug Administration has approved a new formulation of a drug made by Genentech for rheumatoid arthritis that can be injected into the skin.

SOUTH SAN FRANCISCO, Calif. — The Food and Drug Administration has approved a new formulation of a drug made by Genentech for rheumatoid arthritis that can be injected into the skin.

Genentech announced the approval of a subcutaneous formulation of Actemra (tocilizumab) in adults for adults with moderate RA who have not found sufficient relief by taking such disease-modifying antirheumatic drugs as methotrexate. Like the intravenous formulation of Actemra, the new version can be used alone or with drugs like methotrexate.

May 15, 2013

The Food and Drug Administration has approved a drug for a type of lung cancer.

SOUTH SAN FRANCISCO, Calif. — The Food and Drug Administration has approved a drug for a type of lung cancer.

Roche subsidiary Genentech and the U.S. subsidiary of Japan's Astellas Pharma announced the approval of Tarceva (erlotinib) for advanced non-small cell lung cancer whose tumors have mutations that activate the epidermal growth factor receptor. The FDA also approved a test to detect the mutation.

The drug was already approved for advanced NSCLC that did not exhibit the mutation.

 

April 30, 2013

The Food and Drug Administration has approved a drug made by Genentech for a rare form of arthritis in children, the company said Tuesday.

SOUTH SAN FRANCISCO, Calif. — The Food and Drug Administration has approved a drug made by Genentech for a rare form of arthritis in children, the company said Tuesday.

Genentech, a subsidiary of Swiss drug maker Roche, announced the approval of Actemra (tocilizumab) for polyarticular juvenile idiopathic arthritis in children ages 2 years and older, either alone or combined with the generic drug methotrexate.

October 12, 2012

The Food and Drug Administration has approved a new use for a drug made by Roche division Genentech.

SOUTH SAN FRANCISCO, Calif. — The Food and Drug Administration has approved a new use for a drug made by Roche division Genentech.

The drug maker said Friday that the FDA had approved Actemra (tocilizumab) for adults with moderately to severely active rheumatoid arthritis who have not responded adequately to one or more disease-modifying antirheumatic drugs. The drug was already approved for systemic juvenile idiopathic arthritis.

October 10, 2012

Waxelene, a petroleum jelly alternative, now is being sold in Bed Bath & Beyond retail stores, the company has announced.

SAN FRANCISCO, Calif. — Waxelene, a petroleum jelly alternative, now is being sold in Bed Bath & Beyond retail stores, the company has announced. This brings the total count of retail outlets carrying Waxelene to more than 800 across all 50 U.S. states and Canada.
 

November 28, 2011

Zion Health, a maker of natural minerals skin care products, has announced the launch of its Adama Minerals clay body care line at Whole Foods in San Rafael, Calif.

SAN FRANCISCO, Calif. — Zion Health, a maker of natural minerals skin care products, has announced the launch of its Adama Minerals clay body care line at Whole Foods in San Rafael, Calif.

The announcement comes on the heels of a recent agreement with Willner Chemists Health Food Store to offer Zion Health’s complete Adama line at its Chicago stores.